BioSpace News Archive

Kura Oncology, Inc today announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company’s menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).

Vivos Therapeutics, Inc. today announced it plans to release its first quarter 2024 financial results after market close today, Tuesday, May 14, 2024.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced topline data from a 12-week, randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) conducted at Massachusetts General Hospital evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF).

Profound Medical Corp. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the Company’s second TULSA-AI module, Contouring Assistant, for use in conjunction with its TULSA-PRO® system.

Alimera Sciences, Inc. today announced financial results for the first quarter of 2024.

MiNK Therapeutics, Inc. today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update.

Pyxis Oncology, Inc. today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Delcath Systems, Inc. today reported financial results and business highlights for the first quarter ended March 31, 2024.

Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, announced the publication of a patient-focused global consensus statement – ‘Time to Act: A Global Patient-Focused Consensus for Improving the Care of Cutaneous T-Cell Lymphoma '.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency.